On February 4, 2025, IceCure Medical Ltd. announced its participation in the 2025 Society of Interventional Oncology (SIO) Annual Meeting, which took place from January 29 to February 3, 2025. During the meeting, two independent studies demonstrating ProSense®'s safety and efficacy in breast cancer were presented as poster presentations. One of these, a study performed in the Netherlands titled 'The Treatment of Breast Cancer with Percutaneous Thermal Ablation: Results of the THERMAC trial,' was awarded 'Highest Scoring Abstract' in the 'Other Category.'
The THERMAC trial's conclusion was particularly significant, as it found cryoablation to be the only thermal ablative technique that satisfied the requirements to warrant a randomized Phase 3 trial comparing thermal ablation with surgery. This finding underscores the strong potential of ProSense® as a non-surgical alternative for breast cancer treatment. IceCure also sponsored a Breast Cryoablation Mini Master Class at the event, providing hands-on training.
IceCure's CEO, Eyal Shamir, noted the heightened level of interest in ProSense® from doctors who may employ it upon potential FDA approval in the U.S. The research presented at SIO, a global medical conference with high attendance by U.S. physicians, indicates increasing awareness and eagerness to adopt ProSense®, especially for breast cryoablation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.